News | Radiation Therapy | June 29, 2017

Multiple market reports indicate that as doctors discover new ways to utilize Gamma Knife radiosurgery, the global market for this innovative surgical method is growing.

Multiple Uses for Gamma Knife to Drive Market Growth Through 2025

June 29, 2017 — Due to its widespread success in treating several types of brain cancer, global market growth for Gamma Knife radiosurgery involving the head is expected to exceed $364.8 million by 2025. As more patients seek treatment at facilities that offer Gamma Knife radiosurgery, the market is forecast to grow at a compound annual growth rate (CAGR) of 9.2 percent, according to a new report from public relations firm OpenPR.

In terms of geographical location, North America has traditionally led market revenue share, accounting for over 29.2 percent of revenue in 2014, according to the report. A separate report from Future Market Insights indicates that by 2025, treatment of brain metastasis is expected to account for over $285.7 million in the United States market alone. However, as more patients worldwide are treated using Gamma Knife for a variety of medical conditions (for example, brain metastases, benign brain tumors such as pituitary adenomas, meningiomas and acoustic neuromas), both the European and Asia Pacific markets are expected to expand at CAGRs of 7.7 percent and 10.5 percent, respectively.(1)

A large part of this growth is the confirmation of the Gamma Knife an effective treatment option for a wide variety of medical conditions that benefit from a precision approach. Beyond its use as a successful therapy for metastatic brain tumors, the Gamma Knife has provided powerful results to patients suffering from trigeminal neuralgia, movement disorders and arteriovenous malformations, according to the San Diego Gamma Knife Center.

Kenneth Ott, MD, FACS, neurosurgeon at SDGKC, said, “The need for the radiosurgical treatment of metastatic brain tumors is vast and growing. Radiosurgery will also play an important part in the emerging field of neuro-augmentation. Stereotactic functional neurosurgery for pain, obsessive compulsive disorders, seizure disorders and other functional brain disorders will provide further patients to Gamma Knife facilities.”

Additionally, as more patients become aware of the advantages of radiosurgery, there is an increasing demand for this minimally invasive surgical method which has proven to be painless and less time-consuming. Support from governmental agencies, which are increasingly interested in initiatives focused on advancing the practice of radiosurgery, will further drive market growth as more healthcare facilities receiving government funding turn to the practice, according to the FMI report.

“As the nationwide cost of medical care and facilities continued to increase, it is increasingly important to healthcare facilities to provide cost-efficient treatment, such as radiosurgery,” said Ott. “Single treatment in a few hours, in an outpatient facility avoids the cost of in-patient care and the complications necessitated by open surgery. Patients are increasingly aware that co-pay and deductible costs are reduced with Gamma Knife radiosurgery.”

For more information: www.sandiegogammaknife.com


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now